Relay Therapeutics (RLAY) Projected to Post Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.3964) per share and revenue of $1.62 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The firm had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.96 million. On average, analysts expect Relay Therapeutics to post ($1.61) EPS for the current fiscal year and ($1.62) EPS for the next fiscal year.

Relay Therapeutics Stock Performance

Shares of Relay Therapeutics stock opened at $19.69 on Thursday. The company has a market cap of $4.31 billion, a P/E ratio of -12.54 and a beta of 1.72. Relay Therapeutics has a one year low of $5.95 and a one year high of $21.27. The firm has a fifty day moving average of $18.57 and a two-hundred day moving average of $14.84.

Insiders Place Their Bets

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 17,717 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $18.59, for a total transaction of $329,359.03. Following the completion of the transaction, the chief financial officer owned 105,134 shares of the company’s stock, valued at approximately $1,954,441.06. This trade represents a 14.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Sanjiv Patel sold 48,199 shares of the business’s stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $18.10, for a total value of $872,401.90. Following the completion of the transaction, the chief executive officer directly owned 471,301 shares of the company’s stock, valued at approximately $8,530,548.10. This trade represents a 9.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 6,144,870 shares of company stock worth $119,102,319. 5.04% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on RLAY shares. Citizens Jmp lifted their target price on shares of Relay Therapeutics from $21.00 to $26.00 and gave the company a “market outperform” rating in a report on Monday, August 10th. Citigroup reissued a “market outperform” rating on shares of Relay Therapeutics in a report on Monday, August 10th. JPMorgan Chase & Co. raised their price objective on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, October 2nd. Finally, Guggenheim reaffirmed a “buy” rating on shares of Relay Therapeutics in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.92.

About Relay Therapeutics

Relay Therapeutics, Inc is a biotechnology company focused on discovering and developing medicines for cancer and other serious diseases. The company uses its Dynamo platform, which combines structural biology, computational modeling, machine learning and experimental science to study how proteins move and interact. Relay aims to use this approach to identify precisely targeted therapies, including medicines designed to bind to previously difficult-to-drug sites.

The company’s pipeline has primarily focused on oncology, including investigational small-molecule therapies directed at cancer-driving proteins and signaling pathways.